All In Biotech

Drug Trial Radar · NCT04556526

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

A Phase 3 Open-label Randomized Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,031 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,031

Actual

Start

Oct 5, 2020

Primary completion

Mar 2, 2023

Study completion Mar 2, 2023

Sponsor

Lead sponsor
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Center for Family Health Research (CFHR); Coalition for Epidemic Preparedness Innovations; Emory University
First posted
Sep 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo \[Group A\]) and in control women (unvaccinated pregnant women \[Group B\]); and b) to assess adverse neonatal/infant outcomes in neonates/infants born to women randomized to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo \[Group A\]) and in neonates/infants born to control women (unvaccinated during pregnancy \[Group B\]).

Conditions

  • Healthy

Interventions

  • Ad26.ZEBOVBiological

    Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.

  • MVA-BN-FiloBiological

    Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Maternal DeathsTime frame: Up to 6 weeks post-completion/termination of pregnancy
  2. Percentage of Participants with Spontaneous AbortionTime frame: Up to 6 weeks post-completion/termination of pregnancy
  3. Percentage of Participants with StillbirthTime frame: Up to 6 weeks post-completion/termination of pregnancy
  4. Percentage of Participants on the Pathways to Preterm BirthTime frame: Up to 6 weeks post-completion/termination of pregnancy
  5. Percentage of Participants with Pre-eclampsia/ eclampsiaTime frame: Up to 6 weeks post-completion/termination of pregnancy
  6. Percentage of Participants with Antenatal BleedingTime frame: Up to 6 weeks post-completion/termination of pregnancy
  7. Percentage of Participants with Postpartum HemorrhageTime frame: Up to 6 weeks post-completion/termination of pregnancy
  8. Percentage of Newborns with Major Congenital Malformations born to ParticipantsTime frame: At birth
  9. Percentage of Newborns Small for Gestational age (SGA) born to ParticipantsTime frame: At birth
  10. Percentage of Newborns with Low Birth Weight born to ParticipantsTime frame: At birth
  11. Percentage of Newborns with Preterm Birth born to ParticipantsTime frame: At birth
  12. Percentage of Neonatal Deaths in Neonates Born to ParticipantsTime frame: Up to 28 days
  13. Percentage of Infants (of Participants) who Fail to ThriveTime frame: From birth up to 14 weeks of age

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Gihundwe District Hospital

    Cuangugu, Rwanda

  • Gisenyi Hospital

    Gysenyi, Rwanda

  • Center for Family Health Research/Project San Francisco

    Kigali, Rwanda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.